Novartis to buy Chinook for $3.5 billion to boost late-stage pipeline
Chinook Therapeutics, Inc., a biopharmaceutical company specializing in the discovery, development, and commercialization of precision drugs for kidney diseases, today announced that it has entered into a merger agreement and
